ERBB2 and cancer: Various small molecular proteins that induce changes in cell conformation also affect key downstream signaling pathways, such as the overactivation of the HER2-SHCBP1-PLK1 axis by SHC linker protein 1 (SHC1), representing a novel mechanism of cancer resistance to trastuzumab.